Drug repurposing for Alzheimer's disease: a Delphi consensus and stakeholder consultation.

ABSTRACT:

Background

Alzheimer's disease (AD) is an escalating global challenge, with more than 40 million people affected, and this number is projected to increase to more than 100 million by 2050. While amyloid-targeting antibody treatments (lecanemab and donanemab) are a significant step forward, the benefits of these therapies remain limited. This highlights the necessity for safe and effective compounds that offer greater therapeutic benefits to the majority of individuals with or at risk of AD. Drug repurposing allows for a cost-effective, time-efficient strategy to accelerate the availability of treatments, owing to the availability of safety information.

Method

This study focuses on the third iteration of the Delphi consensus programme aimed at identifying new high-priority dr

SUBMITTER: Corbett A 

PROVIDER: S-EPMC12625010 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature